Kura Oncology Q4 Revenues Seen Falling 44.7% as EPS Loss Widens to $0.72
Kura Oncology’s Q4 EPS is forecast to be a $0.72 loss per share, marking a 227% year-over-year decline, while revenues are seen at $29.81 million, down 44.7%. Consensus EPS estimates have been revised down 552.4% over 30 days, yielding an Earnings ESP of -13.29% and a Zacks Rank of 4.
1. Q4 Forecast Overview
Kura Oncology is projected to report a Q4 loss of $0.72 per share, representing a 227% year-over-year decline, with revenues expected at $29.81 million, down 44.7% from December 2024.
2. Estimate Revision Trends
Analysts have lowered their EPS outlook by 552.4% over the past 30 days, reflecting diminishing revenue visibility and caution around near-term pipeline developments.
3. Earnings ESP and Zacks Rank
The company’s Earnings ESP stands at -13.29%, and its Zacks Rank of 4 signals low confidence in an EPS beat, reducing the likelihood of positive stock momentum post-release.